Compositions of CPG and saponin adjuvants and uses thereof

Details Compositions of CPG and saponin adjuvants and uses thereof Compositions of CPG and saponin adjuvants and uses thereof

2006-05-23

2006-05-23

Wilson, Michael (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S184100, C424S278100

Reexamination Certificate

active

07049302

ABSTRACT:
Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.

REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5273965 (1993-12-01), Kensil et al.
patent: 5352449 (1994-10-01), Beltz et al.
patent: 5443829 (1995-08-01), Kensil et al.
patent: 5583112 (1996-12-01), Kensil et al.
patent: 5650398 (1997-07-01), Kensil et al.
patent: 5808024 (1998-09-01), Sasaki et al.
patent: 5968909 (1999-10-01), Agrawal et al.
patent: 5977081 (1999-11-01), Marciani
patent: 6013258 (2000-01-01), Urban et al.
patent: 6231859 (2001-05-01), Kensil
patent: 6406705 (2002-06-01), Davis et al.
patent: 6524584 (2003-02-01), Kensil
patent: 6544518 (2003-04-01), Gerard et al.
patent: 6558670 (2003-05-01), Friede et al.
patent: 6645495 (2003-11-01), Kensil et al.
patent: 2002/0164341 (2002-11-01), Davis et al.
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0161834 (2003-08-01), Friede et al.
patent: 2003/0224010 (2003-12-01), Davis et al.
patent: 9908885 (1999-04-01), None
patent: 1005368 (1998-03-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 99/58118 (1999-11-01), None
patent: WO 99/61056 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/62800 (2000-10-01), None
patent: WO 02/32450 (2002-04-01), None
Kensil (AIDS Research Rev., 1993, vol. 3, Koff, ed., New York, NY, p. 379-390.
Kensil (J. Immunol., Jan. 15, 1991, vol. 146, No. 2, p. 431-437.
Definition of “explicit” by Merriam-Webster Online.
Definition of “chemical modification” by Stedman's Medical dictionary.
Chu et al., CpG oligodeoxynucleotides act as ajuvants that switch on T helper 1 (Th1) immunity, 1997, J. EXP. MED., vol. 186, No. 10, pp. 1623-1631.
Weiner et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization, Spt. 1997,Proc. Natl. Acad. Sci., vol. 94 pp. 10833-10837.
U.S. Appl. No. 09/760,506, filed Jan. 12, 2001, Kensil et al.
Agrawal et a;., 1988, Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl A{umlaut over (c)}ad Sci U.S.A. 85(19):7079-7083.
Agrawal S. 1992, Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10(5):152-158.
Beaucage et al., 1981, Deoxynucleotide phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis. Tet. Let. 22:1859-1862.
Boggs et al., 1997, Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7(5):461-471.
Campbell & Peerbaye, 1992, Saponin.Res. Immuno. 143:526-530.
Carson et al., 1997, Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 186(10):1621-1622.
Chavali & Campbell, 1987, Immunomodulatory Effects of Orally-Administered Saponins and Nonspecific Resistance Against Rabies Infection.Int. Archs. Allergy Appl. Immun. 84:129-134.
Chavali et al., 1988, Immunopotentiation by Orally-AdministeredQuillajaSaponins : Effects in Mice Vaccinated Intraperitoneally Against Rabies.Clin. Exp. Immunol. 74:339-343.
Chavali et al., 1987, AnIn VitroStudy of Immunomodulatory Effects of Some Saponins.Int. J. Immunopharmac. 9(6):675-683.
Dalsgaard, K. 1978, A study of the isolation and characterization of the saponinq1uil a . Acta Veterinia Scandinavica69:1-40.
Elkins et al., 1999, Bacterial DNA containing CpG motiffs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 162(4):2291-2298.
Froehler B, 1986, Deoxynulceoside H-phosphate diester intermediates. Nucleic Acids Res. 14(13):5399-5407.
Froehler et al., 1986, Synthesis of DNA via deoxynucleoside H-phosphonate method. Tet. Let. 29:2619-2622.
Gaffney et al., 1988, Large-scale oligonucleotides synthesis by the H-Phosphonate method. Tet. Let. 29:2619-2622.
Garegg et al., 1986, Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tet. Let. 27:4051-4054.
Garegg et al., 1986, Nucleoside H-phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tet. Let. 27:4055-4058.
Goodchild, J. 1990, Conjugates of oligonucleotides: a review of their synthesis and properties. Bioconjugate Chem. 1:165.
Higuchi et al. Structure of desacylsaponins obtained fron the bark ofQuillaja saponaria. Phytochemistry 26:229-235.
Kensil et al., 1992, Structure/Function relationships in adjuvants fromQuillaja saponaria Molina. Vaccine 92 (Cold Spring Harbor Laboratory Press) pp. 35-40.
Kim et al., 2001, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUCI-KLH and GD3-KLH conjugates. Vaccine. 19(4-5):530-537.
Kirby et al., Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonists ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol. 1996 Nov:7(6):513-525.
Klinman et al., 1996, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 93(7):2879-2883.
Kreig et al., 1996, Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6(2):133-139.
Krieg et al., 1998, CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 161(5):2428-2434.
Lipkin, 1995, “Vegemania: Scientists Tout the Heath Benefits of Saponins”,Science News148:392-393.
Maharaj et al., 1986, Immune Response of Mice to Inactivated Rabies Vaccine Administered Orally: Potentiation byQuillajaSaponin.Can. J. Microbiol. 32:414-420.
Marciani et al., 1991, Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine. 9(2):89-96.
Newman et al., 1992, Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte response. J Immunol. 148(8):2357-2362.
Rao & Sung, 1995, Saponins as Anticarcinogens.J. Nutr. 125:717S-725S.
Uhlmann et al., Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. 9:544-584.
Hemmi et al., 2000, “A Toll-like receptor recognizes bacterial DNA,”Nature408:740-5.
Liu et al., 2002, “QS-22 structure/function studies: effect of acylation on adjuvant activity,”Vaccine20:2808-15.
Soltysik et al., 1995, “Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function1”Vaccine13:1404-10.
Wagner, 2001, “Toll meets bacterial CpG-DNA,”Immunity14:499-502.
Bomford et al., 1992, “Adjuvanticity and ISCOM formation by structurally diverse saponins”,Vaccine10:572-577.
Charlotte Read Kensil, et al, 1993 “Novel Adjuvants fromQuillaja SaponariaMolina”, Aids Research Review, vol. 3: 279-389.
Charlotte Read Kensil, et al, 1991“Separation and Characterization of Saponins with Adjuvant Activity fromQuillaja saponariaMolina Cortex”, Journal of Imm., vol. 146, 431-437, No. 2.
Klinman D.M. “Therapeutic applications of CpG—containing oligodeoxynucleotides”, Antisense and Nucleic Acid Drug Development, (1998 APR) 8 (2) 181-4, XP002128519, the whole document.
Kreig A.M. et al: “The role of CpG dinucleotides in DNA vaccines, &#x

Affiliated with

Also associated with

Rating

Compositions of CPG and saponin adjuvants and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of CPG and saponin adjuvants and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of CPG and saponin adjuvants and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3587858